Czech National Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.7M Buy
28,442
+989
+4% +$673K 0.1% 190
2026
Q1
$21.2M Buy
27,453
+878
+3% +$672K 0.14% 135
2025
Q4
$20.5M Buy
26,575
+702
+3% +$477K 0.13% 132
2025
Q3
$14.5M Buy
25,873
+489
+2% +$276K 0.1% 180
2025
Q2
$13.3M Buy
25,384
+1,220
+5% +$681K 0.1% 178
2025
Q1
$15.3M Buy
24,164
+1,338
+6% +$920K 0.14% 141
2024
Q4
$16.3M Buy
22,826
+1,209
+6% +$1.01M 0.15% 125
2024
Q3
$22.7M Buy
21,617
+1,405
+7% +$1.56M 0.23% 84
2024
Q2
$21.2M Buy
20,212
+1,624
+9% +$1.57M 0.24% 81
2024
Q1
$17.9M Sell
18,588
-178
-0.9% -$169K 0.23% 92
2023
Q4
$16.5M Buy
18,766
+109
+0.6% +$89.8K 0.24% 94
2023
Q3
$15.4M Buy
18,657
+5,885
+46% +$4.63M 0.24% 87
2023
Q2
$9.18M Buy
12,772
+107
+0.8% +$82.5K 0.21% 101
2023
Q1
$10.4M Buy
12,665
+131
+1% +$98.8K 0.26% 89
2022
Q4
$9.04M Buy
12,534
+77
+0.6% +$56.8K 0.24% 99
2022
Q3
$8.58M Buy
+12,457
New +$7.84M 0.25% 88

Other funds holding REGN

Czech National Bank's REGN Position: Q2 2026 in Review

Czech National Bank increased its Regeneron Pharmaceuticals (REGN) stake by 3.6% in Q2 2026, buying an estimated $673K and bringing the position to 28,442 shares worth $17.7M. The position accounts for 0.1% of the portfolio, ranked #190.

Czech National Bank first reported a position in REGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $22.7M in Q3 2024. 406 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Czech National Bank held 28,442 shares of Regeneron Pharmaceuticals worth $17.7M as of Q2 2026.
  • Czech National Bank bought 989 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $673K.
  • Regeneron Pharmaceuticals made up 0.1% of Czech National Bank's portfolio in Q2 2026, its #190 holding.
  • Czech National Bank first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Czech National Bank's Regeneron Pharmaceuticals position peaked at $22.7M in Q3 2024.
  • 406 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Czech National Bank's 13F filing for Q2 2026, filed 8 Jul 2026.